Australia markets closed

SNY Mar 2023 42.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
4.50000.0000 (0.00%)
As of 12:09PM EST. Market open.
Full screen
Previous close4.5000
Open4.5000
Bid0.0000
Ask0.0000
Strike42.00
Expiry date2023-03-17
Day's range4.5000 - 4.5000
Contract rangeN/A
Volume8
Open interest11
  • Motley Fool

    Why Shares of Provention Bio Went Up 30.3% in November

    Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.

  • GlobeNewswire

    Press Release: Statement from Sanofi regarding: rule 2.12 of the takeover rules

    THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE "TAKEOVER RULES"). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DECEMBER 2, 2022 Statement from Sanofi regarding: rule 2.12 of the takeover rules Paris, December 2, 2022. As required by Rule 2.12 of the Takeover Rules, Sanofi S.A.

  • Bloomberg

    Horizon Therapeutics in Separate Sale Talks With Amgen, Sanofi, J&J

    (Bloomberg) -- Horizon Therapeutics Plc rose by the most in more than three years after the drug developer disclosed it’s in talks with a trio of potential suitors about a possible sale of the company.Most Read from BloombergScientists Revive 48,500-Year-Old ‘Zombie Virus’ Buried in IceAn Arizona County’s Refusal to Certify Election Results Could Cost GOP a House SeatStock Traders Cheer Powell’s Risk-Friendly Shift: Markets WrapNYC Becomes One Billionaire Family’s Haven From China Property Crash